Literature DB >> 12183721

Protein insufficiency and linear growth restriction in phenylketonuria.

Georgianne L Arnold1, Catherine J Vladutiu, Russell S Kirby, Eileen M Blakely, Jane M Deluca.   

Abstract

OBJECTIVES: To study the role of protein sufficiency, age, calorie sufficiency, and phenylalanine levels in children with phenylketonuria (PKU) and determine how these affect linear growth.
METHODS: Age, growth measures, plasma prealbumin, and mean phenylalanine levels were analyzed from a chart review of 38 children with early and continuously treated PKU.
RESULTS: A regression model was calculated investigating the effects of prealbumin, age, body mass index, and mean phenylalanine level on height. In this model, plasma prealbumin of <20 was associated with a loss of 45 height percentiles, whereas age and body mass index also had smaller but statistically significant effects. Prealbumin was correlated with height and age such that children with lower prealbumin levels were shorter and younger. There was no significant correlation between age and height or mean plasma phenylalanine level and height. A prealbumin level of 20 mg/dL appeared to constitute a threshold level, below which height growth was very significantly impaired.
CONCLUSIONS: There is a strong relation between protein insufficiency, as determined by plasma prealbumin levels, and linear growth impairment. We suggest that a plasma prealbumin level of at least 20 mg/dL is necessary for optimal growth in children with PKU.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183721     DOI: 10.1067/mpd.2002.126455

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

Review 1.  Nutrition therapy of organic acidaemias with amino acid-based formulas: emphasis on methylmalonic and propionic acidaemia.

Authors:  Steven Yannicelli
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

2.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

3.  Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.

Authors:  Patrick Solverson; Sangita G Murali; Adam S Brinkman; David W Nelson; Murray K Clayton; Chi-Liang Eric Yen; Denise M Ney
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-31       Impact factor: 4.310

Review 4.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

5.  Predictive equations underestimate resting energy expenditure in female adolescents with phenylketonuria.

Authors:  Meghan E Quirk; Brian J Schmotzer; Rani H Singh
Journal:  J Am Diet Assoc       Date:  2010-06

6.  Tissue-specific activation of mitogen-activated protein kinases for expression of transthyretin by phenylalanine and its metabolite, phenylpyruvic acid.

Authors:  Joo Won Park; Mi Hee Lee; Jin Ok Choi; Hae Young Park; Sung Chul Jung
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

Review 7.  Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature.

Authors:  M Huemer; C Huemer; D Möslinger; D Huter; S Stöckler-Ipsiroglu
Journal:  J Inherit Metab Dis       Date:  2007-07-11       Impact factor: 4.982

Review 8.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

9.  Chronic kidney disease in adolescent and adult patients with phenylketonuria.

Authors:  Julia B Hennermann; Sylvia Roloff; Jutta Gellermann; Ilka Vollmer; Elke Windt; Barbara Vetter; Ursula Plöckinger; Eberhard Mönch; Uwe Querfeld
Journal:  J Inherit Metab Dis       Date:  2012-11-09       Impact factor: 4.982

10.  A long-term study of bone mineral density in patients with phenylketonuria under diet therapy.

Authors:  Hala M Koura; Nagwa Abdallah Ismail; Ashraf F Kamel; Azza M Ahmed; Amal Saad-Hussein; Laila K Effat
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.